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Human insulin is provided by the Brazilian Public Health System (BPHS) for the treatment of diabetes, 
however, legal proceedings to acquire insulin analogs have burdened the BPHS health system. The 
aim of this study was to perform a cost-effectiveness analysis to compare insulin analogs and human 
insulins. This is a pharmacoeconomic study of cost-effectiveness. The direct medical cost related to 
insulin extracted from the Ministry of Health drug price list was considered. The clinical results, i.e. 
reduction in glycated hemoglobin (HbA1c), were extracted by meta-analysis. Different scenarios were 
structured to measure the uncertainties regarding the costs and reduction in HbA1c. Decision tree was 
developed for sensitivity of Incremental Cost Effectiveness Ratio (ICER). A total of fifteen scenarios 
were structured. Given the best-case scenario for the insulin analogs, the insulins aspart, lispro, glargine 
and detemir showed an ICER of R$ 1,768.59; R$ 3,308.54; R$ 11,718.75 and R$ 2,685.22, respectively. 
In all scenarios in which the minimum effectiveness was proposed, lispro, glargine and detemir were 
dominant strategies. Sensitivity analysis showed that the aspart had R$ 3,066.98 [95 % CI: 2339.22; 
4418.53] and detemir had R$ 6,163.97 [95% CI: 3919.29; 11401.57] for incremental costs. We concluded 
there was evidence that the insulin aspart is the most cost-effective.
Keywords: Diabetes Mellitus/treatment/cost-effectiveness/evaluation. Prolonged Action Insulin. Short 
Action Insulin. Brazilian Public Health System.
INTRODUCTION
Diabetes Mellitus (DM) is a group of chronic 
metabolic disorders that cause hyperglycemia. If not 
controlled, DM may trigger vascular complications and 
impair the function of organs such as the kidneys, brain 
and heart (ADA, 2016; SBD, 2016; WHO, 2016a). 
Approximately 415 million people worldwide have DM, 
75% from which live in low- and middle-income countries 
(IDF, 2016). In Brazil, the prevalence is 8.1% (WHO, 2016b).
The annual direct costs to the Brazilian Public 
Health System (BPHS) with DM management reaches 
14.8 billion Reais, which represents outpatient spending 
of R$ 8,010.00/patient/year (SDB, 2016). This amount 
includes direct costs related to examinations, medicines 
and consultations, non-medical direct costs, such as 
transportation and absenteeism and indirect health care 
costs, such as those generated by the complications of 
uncontrolled DM. The treatment effectiveness results 
in sustained reduction in glycosylated haemoglobin 
(HbA1c) and cost savings associated to complications and 
to indirect costs which are the highest costs that burden 
the BPHS (Rascati, 2010; Do Livramento, Saleh, 2011; 
Wagner et al., 2001; Obreli-Neto et al., 2015; SDB, 2016).
DM type 1 (DMT1) is usually an autoimmune 
disorder that results in absolute insulin deficiency. DM type 
2 (DMT2) is characterized by the resistance of tissues to 
the insulin and/or the relative deficiency of insulin. People 
with DMT1 are insulin-dependent and insulinization is a 
therapeutic option for DMT2. (ADA, 2016; SBD, 2016). 
Therapies with human Neutral Protamine Hagedorn 
(NPH) insulin, Regular (R) insulin and insulin analogs 
foster discussion about the DM treatment effectiveness 
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and involved costs. NPH, a slow-acting insulin, has 
unfavorable characteristics such as its erratic absorption, 
causing unpredictable glycemic variations. R insulin has 
faster action and is used to control postprandial glycemia, 
but it presents relatively slow absorption considering its 
indication. This absorption and the irregular feeding of 
some patients can result in hypoglycemia and therapeutic 
failures (SBD, 2011).
Human NPH and R insulin are provided by the BPHS. 
However, access to human insulin analogs generally occurs 
through lawsuits (Do Livramento, Saleh, 2011; Figueiredo, 
Osorio-de-Castro, Pepe, 2013). These unforeseen expenses 
in the health budget with higher cost medicines burden the 
BPHS and this increase of expenses to the BPHS has been 
associated with arbitrary decisions related to provision 
of the insulin analogs. They have been available through 
judicial processes in different regions and municipalities 
of Brazil. The number of lawsuits involving lispro and 
glargine insulins is twice the number of lawsuits to require 
other insulin analogs (Lima et al., 2015). Decision-making 
for health care should be a rational process which does 
not result in excessive and unnecessary health care costs 
because this can compromise the system equity and the 
access to health (Shafie et al., 2016). The decision to provide 
or to incorporate to BPHS for any insulin analog should 
be supported by economic analysis and clinical evidence 
(Brasil, 2014).
In this context, the knowledge about cost-effectiveness 
of insulin analogs can subsidize health planning and 
possible incorporation of insulin analogs into the BPHS. 
The aim of this study was to perform a cost-effectiveness 
analysis to compare insulin analogs and human insulins.
METHODS
This is a pharmacoeconomic study of cost-
effectiveness to perspectives of BPHS. This study was 
developed based on data from the literature concerning the 
treatment of DM with insulin therapy. The cost data refer 
to the month of June 2016 and were recorded in monetary 
values in Brazilian currency, the Real. The calculation 
referred to the cost per patient/year. 
For this study the direct medical costs of insulin 
treatment were ranked. The therapeutic regimen for each 
type of insulin was measured in accordance with the dose 
described as an International Unit (IU) per kg of the patient, 
considering for the calculation of the annual cost, 360 days 
of a year and body weight of 70 kg, being the mean of the 
normal distribution for the Brazilian population, according 
to the Brazilian Institute of Geography and Statistics (Brasil, 
2016). Thus, the cost per IU of the drug was multiplied by 
the mean daily dose in IU recommended for each type of 
insulin, and calculated per patient/year. The mean dose 
values  assigned to each type of insulin were extracted 
from the studies used in the meta-analysis by Sanches et al. 
(2013) (Anderson Jr et al., 1997; Home, 2000; Hermansen 
et al., 2004; Heller, Koenen, Bode, 2009).
Data related to the reduction of HbA1c were used to 
compare treatment with human insulin and treatment with 
insulin analogs, being obtained from the meta-analysis by 
Sanches et al. (2013). The meta-analysis examined sixteen 
studies, totaling 5,733 patients using rapid-acting insulin 
analogs (glulisine, arpart, lispro) and 4,771 patients using 
long-acting insulin analogs (glargine and detemir). The mean 
age was 39.2 years and all patients were receiving diabetes 
treatment with insulin only. Glulisine was excluded from 
this study because it was not analyzed in the meta-analysis, 
being as it was found only in a clinical trial that analyzed 
glulisine vs. insulin R. The meta-analysis considered the 
significance level of 5% and the figures were interpreted 
for 95% confidence interval (Sanches et al., 2013).
The costs were extracted from the Market of 
Regulation of the Market of Medicines (CMED). It 
was considered the price of the sale of medicine to the 
government and the tax rate of 18%, linked to most Brazilian 
states. The values of each insulin existing in the table were 
considered: NPH INSUNORM N (ASPEN PHARMA) 100 
IU mL, 10 mL injectable suspension; Regular INSUNORM 
R (ASPEN PHARMA) 100 IU/mL, 10 mL injectable 
solution; NOVORAPID aspart (NOVO NORDISK) 100 
IU/mL, 10 mL injectable solution; lispro HUMALOG 
(ELI LILLY) 100 IU/mL, 10 mL injectable solution; 
detemir LEVEMIR (NOVO NORDISK) 100 IU/mL, 3 mL 
injectable solution; and glargine VELUXUS (MEDLEY) 
100 IU/mL, 3 mL injectable solution (ANVISA, 2016).
Calculating cost-effectiveness
For cost-effectiveness analysis the Incremental Cost 
Effectiveness Ratio (ICER) was calculated, the calculation 
of which is the ratio of the cost variation by variation of the 
effectiveness, designated by the expression (Rascati, 2010):
The ICER refers to the extra cost with the insulin 
analog in order to obtain an improvement in the outcome, 
the reduction in HbA1c. Thus, it can be understood that 
when there is no higher cost and there is an improvement 
of the outcome, the option becomes dominant in the 
scenario of the analysis, and when there is a higher cost 
and worsening outcome, the option becomes dominated 
in the respective scenario of analysis.
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Simulation of uncertainties
Different scenarios were structured to measure the 
possibilities of variation of costs and reduction in HbA1c 
achieved by each type of insulin (Drummond et al., 2005). 
The calculation of the ICER for variations in cost was 
performed for the mean, minimum, and maximum values, 
which relate to the cost difference between the mean, 
minimum, and maximum values of insulin, respectively. 
The cost was also varied for the largest possible difference 
and smallest possible difference obtained by the difference 
between the lowest cost of human insulin and the highest 
cost of insulin analog, and between the highest cost of 
human insulin and the lowest cost of insulin analog, 
respectively. To compose the scenarios of different 
possibilities for insulin cost-effectiveness, the variation 
in costs was combined with variation of effectiveness, 
whether mean, minimum and maximum, for the reduction 
of HbA1c. The cost-effectiveness threshold was measured 
by the amount of three times the GDP per capita for the 
year 2015 as recommended by the Brazilian Network of 
Technology Assessment in Health (Brasil, 2014).
Sensitivity analysis
Sensitivity analysis was performed in order to 
support decision-making regarding the analysis of ICER 
variation of each type of insulin analog (Drummond et al., 
2005; Rascati, 2010). For this, a decision tree was drawn 
which through the confidence interval for the reduction 
of HbA1c demonstrated the sensitivity of the analysis, 
given the variation of effectiveness. In this model of 
analysis, calculated probabilities were considered with a 
95% confidence interval for the minimum and maximum 
variation in HbA1c, and for the variation in the minimum 
and maximum cost of each insulin types . For construction 
of the decision tree the first node of the tree was defined 
as being the decision node between two representatives of 
each insulin-class of fast and long-acting action. This node 
branched into a probability node related to the probability 
of minimum and maximum effectiveness of each insulin. 
Each probability node branched into a terminal node with 
the probability of variation in maximum and minimum 
cost for each insulin.
The probabilities were obtained within the confidence 
interval itself. For the probability of the minimum value the 
ratio between the minimum value and the sum of the values 
within the interval was calculated, and the probability of the 
maximum value followed the expression: (1 - probability of 
minimum value). Thus, the smaller the amplitude between 
the maximum and minimum values  of the confidence 
interval, the lower the probability for values to differ from 
the mean, both for effectiveness and cost, i.e. the result 
is more consistent with the mean which was used for 
calculating the cost-effectiveness ratio.
RESULTS
When insulin analogs were compared with human 
insulin, fast acing R and long-acting NPH, the insulin 
analogs that presented greater effectiveness were aspart 
and detemir, which showed a further reduction of -0.13% 
[95% CI: -0.17; -0.09] and -0.11% [95% CI: -0.32; 0.11] 
in mean HbA1c, respectively. It should be highlighted that 
among the insulin analogs, aspart and detemir were the 
options that presented the lowest mean cost of treatment 
per patient/year, R$ 665.34 [95% CI: 591.41; 739.26] and 
R$ 1,752.66 [95% CI: 1448.86; 2056.45], respectively. 
It was observed that the highest cost that aspart could 
present was still lower than the lowest cost of the analog 
option analyzed, namely lispro. A similar situation was 
not verified for the long-acting insulin analogs (Table I).
TABLE I ‑ Effectiveness of insulin analogs in reducing HbA1c compared to human insulins and the annual cost for treatment
Insulins Reduction in HbA1c (CI 95 %)
Daily dose IU/Kg 
(CI 95 %)
R$ Cost of treatment patient/year
Minimum Mean Maximum
Fast acting
REGULAR Reference 0.68 (0.62; 0.73) 500.75 549.20 589.59
Aspart -0.13 (-0.17; -0.09) 0.36 (0.32; 0.40) 591.41 665.34 739.26
Lispro -0.08 (-0.24; 0.08+) 0.67 (0.61; 0.70) 1,084.80 1,191.50 1,244.85
Long acting
NPH Reference 0.34 (0.32; 0.36) 258.45 274.60 290.75
Glargine -0.04 (-0.12; 0.05+) 0.33 (0.30; 0.37) 1,995.84 2,195.42 2,461.53
Detemir -0.11 (-0.32; 0.11+) 0.37 (0.31; 0.44) 1,448.86 1,752.66 2,056.45
+ = confidence interval shows that there is a possibility of increased HbA1c. Reference = the glycated reduction values were the 
benchmarks for insulin analogs. Costs were obtained according to the CMED Table 2016 and were calculated for the annual cost 
of treatment in accordance with the recommended regimen for each type of insulin.
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TABLE II ‑ Incremental cost effectiveness in different scenarios for the simulation of the uncertainties in the comparison of insulin 
analogs with human insulin
Mean Effectiveness Minimum Effectiveness Maximum Effectiveness
Aspart Lispro Glargine Detemir Aspart Lispro Glargine Detemir Aspart Lispro Glargine Detemir
Mean Cost 3,005.69 11,461.25 41,155.50 10,940.55 4,341.56 Dominated Dominated Dominated 2,298.47 3,820.42 13,718.50 3,760.81
Minimum 
Cost 2,561.23 10,329.38 37,377.25 8,619.18 3,699.56 Dominated Dominated Dominated 1,958.59 3,443.13 12,459.08 2,962.84
Maximum 








2,312.77 9,925.63 35,156.25 7,811.55 3,340.67 Dominated Dominated Dominated 1,768.59 3,308.54 11,718.75 2,685.22
Largest difference = difference between the lowest cost of human insulin and the highest cost of insulin analog. Smallest difference = difference between the 
highest cost of human insulin and the lowest cost of insulin analog. Dominated = represents the strategy in which the insulin analog had a larger cost and a lower 
effectiveness when compared to human insulin.
Fifteen scenarios were structured for the simulation 
of uncertainty in cost-effectiveness analysis. The mean, 
minimum, and maximum cost combinations, and largest 
and smallest cost difference with the mean, minimum and 
maximum effectiveness of each insulin showed that in face 
of the best-case scenario for the insulin analogs, i.e. least 
difference in cost and maximum effectiveness, the insulins 
aspart, lispro, glargine and detemir showed the ICER of 
R$ 1,768.59; R$ 3,308.54; R$ 11,718.75 and R$ 2,685.22, 
respectively. Additionally, in face of the worst-case 
scenario, i.e. largest cost difference and lowest effectiveness, 
all options were the dominated strategies, except aspart. 
The same was interpreted for all other scenarios in which 
minimal effectiveness was proposed (Table II).
Sensitivity analysis showed that in face of the 
probabilities of the effectiveness and cost variations, 
the insulin analogs aspart, lispro, glargine and detemir 
presented the ICER of R$ 3,066.98; R$ 5,960.39; R$ 
22,414.37; and R$ 6,163.97, respectively. It is possible 
to highlight by sensitivity analysis that the option of the 
most cost effective fast acting insulin analog was aspart 
and long acting was detemir (Figure 1).
DISCUSSION
In direct cost analysis for the treatment of DM was 
possible to predict with 95% certainty that the minimum cost 
of insulin analog options was not less than the maximum 
cost of human insulin options, and the same evidence holds 
in the comparison between aspart and lispro. According 
to Holden et al. (2011), human insulins are preferred over 
insulin analogs in merit of cost savings to the government, 
given the expected effectiveness for the treatment of DM.
In all scenarios in which the lowest possible 
effectiveness is projected, the options lispro, glargine and 
detemir were dominated strategies and only aspart had 
ICER in trade-off, able to present an incremental cost for 
additional improvement in the outcome. When considering 
the mean effectiveness range, the most cost effective 
long-acting insulin option was detemir, R$ 14,142.73 and, 
among the fast acting options the most cost effective was 
aspart, R$ 3,698.54, being values added to the treatment 
for an additional reduction of 1 % in HbA1c per patient/
year. In all scenarios, all options had an ICER less than the 
threshold of cost-effectiveness of R$ 86,628.00 (amount 
equal to three times the per capita GDP of the year 2016). 
According to the opinion of the National Commission 
on Technology Incorporation in the BPHS (CONITEC, 
2013), the ICER attributed to insulin analogs are not able 
to exceed the cost-effectiveness threshold.
Considering the best possible scenario for 
comparison of insulin analogs, among the fast-acting and 
long-acting insulins, aspart and detemir were the options 
that presented the best incremental cost effectiveness, 
being R$ 1,768.59 and R$ 2,685.22 per patient/year to 
reduce by an additional 1 % HbA1c respectively. In the 
worst and best scenario, aspart and detemir insulin analogs 
had the lowest ICER compared with lispro and glargine. It 
is important that a 1 % reduction in HbA1c reduces by 43% 
the risk of amputation, in 14% the risk of acute myocardial 
infarction, and in 37% microvascular complications (SBD, 
2016), so that the incremental cost represent the long-term 
economy of resources for the BPHS.
According to the sensitivity analysis by the decision 
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tree, the most cost effective fast-acting insulin analog was 
aspart, R$ 3,066.98 [95% CI: 2339.22; 4418.53] and the 
most cost effective long-acting insulin was detemir, R$ 
6,163.97 [95% CI: 3919.29; 11401.57]. The result in face 
of the uncertainty simulation scenarios was maintained 
with sensitivity analysis, i.e., aspart and detemir were 
the most cost effective from the options. However, it 
was possible to identify increased ICER of aspart and 
FIGURE 1 ‑ Sensitivity analysis structured in a decision tree model for the Incremental Cost Effectiveness Ratio (ICER) of insulin 
analogs. A) structured sensitivity analysis for fast acting insulin analogs. B) Structured sensitivity analysis for long-acting insulin 
analogs. For the construction of the decision tree, the first node of the tree was considered as the decision node (square symbol) 
between the two types of insulin in each category, i.e. fast-acting and long-acting. The respective node of each insulin had a branch 
to two probability nodes (circle symbol), a node associated with the minimum and maximum effectiveness and another with the 
maximum and minimum cost. For the probabilities of each branch the 95 % confidence interval was calculated, based on the range 
between the minimum and maximum reduction of glycated hemoglobin and minimum and maximum cost of insulin. The terminal 
node (triangle symbol) had values in Reais of incremental cost effectiveness for each possibility, taken from Table II. For the 
respective insulin of the dominated strategy when considering minimum effectiveness, the ICER was ranked from the scenario of 
minimum and maximum cost with the mean effectiveness of the insulins.
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detemir in accordance with the probabilities. This positive 
difference in the mean was R$ 61.29 and R$ 4,776.58, 
respectively. When comparing with the worst-case 
scenario, there was a negative difference of R$ 631.56 
and R$ 7,978.76, respectively, and in the best scenario, 
a positive difference of R$ 1,298.39 and R$ 3,478.75 for 
aspart and detemir respectively.
It is important to stick to the scenarios of uncertainties, 
which showed that in the lowest-effectiveness hypothesis, 
the only option not dominated was aspart. This may be 
related to the effectiveness of lispro, which presented no 
evidence of better effectiveness compared with R insulin 
in clinical trials, unlike aspart which promoted significant 
improvement in glycemic control (Gale, 2000; Home, 
Lindholm, Riis, 2000). The same has been shown for long-
acting insulin analogs, which have not presented evidence 
of better efficacy when compared with NPH (Venancio et 
al., 2013).
The investment decision in aspart to improve 
glycemic control in diabetic patients can initially bring 
clinical benefits to patients and future financial benefits 
to the BPHS. However, this decision should have a plan, 
since budget impact studies indicate that the impact of 
the addition of insulin analogs into the BPHS can reach 
about 202.8 million Reais (CONITEC, 2013). In this way, 
the system cannot enjoy adequate capital for the initial 
investment which results in future financial benefits. Any 
poorly planned investment may compromise other sectors 
of health in Brazil.
One of the benefits highlighted for the use of insulin 
analogs over human insulin has been the significant 
reduction in the incidence of cases of hypoglycemia. 
Studies have shown that the improvement occurs in 
episodes of nocturnal hypoglycemia (Crasto et al., 2009; 
SDB, 2011; SDB, 2016). However, due to the data source 
used, this study did not consider episodes of diurnal, 
nocturnal and pre-prandial hypoglycemia, but instead, total 
hypoglycemic episodes. Thus, it is possible to emphasize 
that when evaluating the total episodes of hypoglycemia, 
the options of long and fast-acting insulin analogs poses 
no greater risks than NPH and Regular (Hermansen et al., 
2001; CONITEC, 2013; Venancio et al., 2013).
According to the analysis by the values of Odds 
Ratio (OR) between the comparisons of total episodes of 
hypoglycemia, the meta-analysis used in this study has 
shown: detemir vs. NPH, OR=0.88 [0.52 to 1.51]; glargine 
vs. NPH, OR=1.12 [0.69 to 1.81]; lispro vs. insulin R, 
OR=0.72 [0.21 to 2.55]; and aspart vs. insulin R, OR=0.71 
[0.43 to 1.16]. These results mean that all insulins present 
the same risk to cause hypoglycemia (Sanches et al., 
2013). It is noteworthy that the analysis performed in this 
study did not consider the cost of adverse reactions of the 
insulins.
It is relevant to point out that the assessment of 
cost-effectiveness of this study considered adult diabetic 
individuals, according to analysis performed by meta-
analysis which provided the data for the study. We 
highlight there was no need to obtain other types of costs, 
such as indirect medical costs and non-medical costs 
since, given the perspective of this study (Rascati, 2010; 
CONITEC, 2013). Additionally, the effectiveness of each 
type of insulin was pertinent to insulin monotherapy, 
without adjuvant to DM treatment. 
However, it is noteworthy that this study presents 
well-delineated results consistent with reality for Brazilian 
adult diabetic patients, and insulin without adjuvant 
treatment of DM. A relevant form of costing to the 
perspective of this study was used, in face of the BPHS 
and clinical data with high value of evidence (Savi, Silva, 
2009). In addition, sensitivity analysis was performed 
based on a robust method for decision making, which 
uses statistical and mathematical tools that summarize in 
the decision tree model the best choice (Drummond et al., 
2005; Rascati, 2010).
CONCLUSION
Assessing only the cost of treatment by direct cost 
analysis performed in this study, it was possible to conclude 
that Regular insulin and NPH were the best options for the 
treatment of DM. Still considering direct cost analysis, 
the insulins aspart and detemir were alternatives as the 
best choice among the insulin analog options, and aspart 
presented no possibilities of being more costly than the 
other fast-acting insulin options evaluated. According to 
sensitivity analysis, the best options among the insulin 
analogs were detemir and aspart. However, the insulin 
detemir was a dominated option according to uncertainty 
scenarios. Thus, our study showed there was evidence for 
aspart to be the most cost-effective insulin option when 
targeting an increment in reducing HbA1c and possible 
improvement in glycemic control.
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